|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ubiquitin modifications显示文摘 | Kirby N Swatek David Komander | 2016 | Cell Research2016，26，4： | 77 |
| 2 | Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg显示文摘AIM:To investigate the outcome of palliative chemotherapy in old patients with gastroesophageal cancer at the National Center for Tumor Diseases,Heidelberg.METHODS:Using a prospectively generated database,we retrospectively analyzed 55 patients≥70years under palliative chemotherapy for advanced gastroesophageal cancer at the outpatient clinic of the National Center for Tumor Diseases Heidelberg,Germany between January 2006 and December2013.Further requirements for inclusion were(1)histologically proven diagnosis of gastroesophageal cancer;(2)advanced(metastatic or inoperable)disease;and(3)no history of radiation or radiochemotherapy.The clinical information included Eastern Cooperative Oncology Group performance status(ECOG PS),presence and site of metastases at diagnosis,date of previous surgery and perioperative chemotherapy,start and stop date of first-line treatment,toxicities and consecutive dosage reductions of first-line treatment,response to first-line therapy,date of progression,usage of second-line therapies and date and cause of death.Survival times[progression-free survival(PFS),overall survival(OS)and residual survival(RS)]were calculated.Toxicity and safety were examined.Prognostic factors including ECOG PS,age and previousperioperative treatment were analyzed.RESULTS:Median age of our cohort was 76 years.86%of patients received a combination of two cytotoxic drugs.76 percent of patients had an oxaliplatin-based first-line therapy with the oxaliplatin and 5-fluorouracil regimen being the predominantely chosen regimen(69%).Drug modifications due to toxicity were necessary in 56%of patients,and 11%of patients stopped treatment due to toxicities.Survival times of our cohort are in good accordance with the major phaseⅢtrials that included mostly younger patients:PFS and OS were 5.8 and 9.5 mo,respectively.Survival differed significantly between patient groups with low(≤1)and high(≥2)ECOG PS(12.7 mo vs 3.8 mo,P<0.001).Very old patients(≥75 years)did not show a worse outcome in terms of survival.Patients receiving secondline treatment(51%)had a significantly longer RS than patients with best supportive care(6.8 vs 1.4 mo,P=0.001).Initial ECOG PS was a strong prognostic factor for PFS,OS and RS.CONCLUSION:Old patients with non-curable gastroesophageal cancer should be offered chemotherapy,and ECOG PS is a tool for balancing benefit and harm upfront.Second-line treatment is reasonable. | Anne Katrin Berger Stefanie Zschaebitz Christine Komander Dirk Jger Georg Martin Haag | 2015 | World Journal of Gastroenterology2015，21，16： | 6 |
| 3 | The nuts and bolts of AGC pro- tein kinases 显示文摘 | Pearee L R Komander D Alessi D R | 2010 | Nature reviews Molecular cell biology2010，11，1： | 1 |
| 4 | Breaking the chains: structure and function of the deubiquitinases显示文摘 | KOMANDER D CLAGUE M J URBI S | 2009 | Nature Reviews Molecular Cell Biology2009，10，8： | 1 |
| 5 | The ubiquitin code显示文摘 | Komander D Rape M | 2012 | Annu Rev Biochem2012，81，： | 1 |
| 6 | Atypical ubiquitylation-the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages显示文摘 | Kulathu Y Komander D | 2012 | Nat Rev Mol Cell Biol2012，13，8： | 1 |
| 7 | Structural insights into the catalytic mechanism of a fatuity 18 exochitinase显示文摘 | Van Aalten D M F Komander D Synstad B | | 0，，： | 1 |
| 8 | The ubiquitin code显示文摘 | Komander D Rape M | 2012 | Annu RevBiochem2012，81，： | 1 |
| 9 | Structure of the human Parkin ligasedomain in an autoinhibited state 显示文摘 | Wauer T Komander D | 2013 | EMBO J2013，32，15： | 1 |
| 10 | Breaking the chains: structure and function of the deubiquitinases显示文摘 | Komander D Clague M J Urbe S | 2009 | Nat Rev Mol Cell Biol2009，10，8： | 1 |
| 11 | PDK1, the master regulator of AC, C kinase signal transduction 显示文摘 | Morn A Komander D van Aalten DM | 2004 | Semin Cell Dev BioL2004，15，2： | 1 |
| 12 | The ubiquitin code显示文摘 | Komander D Rape M | 2012 | Annu Rev Biochem2012，，81： | 1 |
| 13 | Structural insights into the catalytic mechanism of a family18 exo-chitinase显示文摘 | Van A Komander D Synstad B | | 0，，： | 1 |
| 14 | Molecular discrimination of structurally equivalent Lys 63-linked and linear polyubiquitin chains显示文摘 | Komander D Reyes-turcu F Licchesi JD | 2009 | EMBO Reports2009，10，5： | 1 |
| 15 | Atypical ubiquitylation:the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages显示文摘 | KULATHU Y KOMANDER D | 2012 | Nat Rev Mol Cell Biol2012，13，8： | 1 |
| 16 | Structure of the A20 OTU domain and mechanistic insights into deubiquitination显示文摘 | Komander D Barford D | 2008 | Biochem J2008，409，1： | 1 |
| 17 | The nuts and bolts of AGC protein kinases显示文摘 | Pearce LR Komander D Alessi DR | 2010 | Nat Rev Mol Cell Biol2010，11，： | 1 |
| 18 | PDK1,the master regulator of AGC kinase signal transduction显示文摘 | Mora A Komander D van Aalten DM | 2004 | Semin Cell Dev Biol2004，15，2： | 1 |
| 19 | The ubiquitin code 显示文摘 | Komander D Rape M | 2012 | Annu Rev Biochem2012，81，20： | 1 |
| 20 | Breaking the chains:structure and function of the deubiquitinases显示文摘 | KOMANDER D CLAGUE M J URBE S | 2009 | Nature ReviewsMolecular Cell Biology2009，10，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员